Skip to main content
. Author manuscript; available in PMC: 2015 Feb 23.
Published in final edited form as: Nucl Med Commun. 2011 Nov;32(11):1046–1051. doi: 10.1097/MNM.0b013e32834a369b

Fig. 4.

Fig. 4

The combination of AZD-2281 (500 nmol/l) with various doses of 131I-tositumomab shows a significant reduction (P<0.05) in cell growth after 24 h with 5 μCi (500 nmol/l) and 10 μCi (0.37MBq) of 131I-tositumomab (line). The combination of 500 nmol/l AZD-2281 with various doses of external beam shows a significant reduction in cell viability for 4 and 12 Gy but not for 8 Gy (bars). *P<0.05 significant difference in RIT with Bexxar, †P<0.05 significant difference in external beam.